LPL gene Pvu II polymorphism and hypertriglyceridemia: a meta-analysis involving 1,640 subjects
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Although lipoprotein lipase (LPL) gene Pvu II polymorphism has been associated with an increased risk of hypertriglyceridemia (HT), there is no clear consensus within the scientific community. Methods: A meta-analysis of 1,640 subjects from six individual studies was conducted to better elucidate the potential relationship between the LPL gene Pvu II polymorphism and HT within the Chinese population. Pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were evaluated by using fixed effect models. Results: Our analysis indicated a significant association between LPL gene Pvu II polymorphism and HT within the Chinese population under allelic (OR, 1.550; 95% CI, 1.320 to 1.830; p = 1.158 × 10–7), recessive (OR, 0.540; 95% CI, 0.390 to 0.750; p = 0.0002), dominant (OR, 1.889; 95% CI, 1.501 to 2.377; p = 5.960 × 10–8), homozygous (OR, 2.167; 95% CI, 1.531 to 3.067; p = 1.242 × 10–5), heterozygous (OR, 1.810; 95% CI, 1.419 to 2.309; p = 1.842 × 10–6), and additive genetic models (OR, 1.553; 95% CI, 1.320 to 1.828; p = 1.158 × 10–7). Conclusions: Because LPL gene Pvu II restriction fragment length polymorphism polymorphism was associated with an elevated risk of HT, the P+ allele carriers of the LPL gene might be predisposed to HT.
Abstract
Background/Aims: Although lipoprotein lipase (LPL) gene Pvu II polymorphism has been associated with an increased risk of hypertriglyceridemia (HT), there is no clear consensus within the scientific community. Methods: A meta-analysis of 1,640 subjects from six individual studies was conducted to better elucidate the potential relationship between the LPL gene Pvu II polymorphism and HT within the Chinese population. Pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were evaluated by using fixed effect models. Results: Our analysis indicated a significant association between LPL gene Pvu II polymorphism and HT within the Chinese population under allelic (OR, 1.550; 95% CI, 1.320 to 1.830; p = 1.158 × 10–7), recessive (OR, 0.540; 95% CI, 0.390 to 0.750; p = 0.0002), dominant (OR, 1.889; 95% CI, 1.501 to 2.377; p = 5.960 × 10–8), homozygous (OR, 2.167; 95% CI, 1.531 to 3.067; p = 1.242 × 10–5), heterozygous (OR, 1.810; 95% CI, 1.419 to 2.309; p = 1.842 × 10–6), and additive genetic models (OR, 1.553; 95% CI, 1.320 to 1.828; p = 1.158 × 10–7). Conclusions: Because LPL gene Pvu II restriction fragment length polymorphism polymorphism was associated with an elevated risk of HT, the P+ allele carriers of the LPL gene might be predisposed to HT.
참고문헌 (22)
- Stancakova A, "Effect of gene polymorphisms on lipoprotein levels in patients with dyslipidemia of metabolic syndrome", Physiol Res, 55, pp.483~490 (2006)
- Helgadottir A, "Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease", Nat Gene, 48, pp.634~639 (2016)
- Gui L, "Association studies on the bovine lipoprotein lipase gene polymorphism with growth and carcass quality traits in Qinchuan cattle", Mol Cell Probes, 30, pp.61~65 (2016)
- Du JK, "Research progress of lipoprotein lipase gene", Yi Chuan, 29, pp.8~16 (2007)
- Fan Y, "Studies on association between lipoprotein lipase gene polymorphisms of Pvu II site and hypertriglyceridemics in Chinese", Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 18, pp.296~298 (2001)
- Wang K, "The relationship between LPL, CETP gene polymorphism and hyperlipidemia in Xinjiang Kazaka people", Chin J Med Guide, 8, pp.255~258 (2006)
- Huang L, "The association of lipoprotein lipase gene polymorphism with hyperlipidemia and dietary predisposition of obesity", Ying Yang Xue Bao, 29, pp.228~231 (2007)
- Cochran WG., "The effectiveness of adjustment by subclassification in removing bias in observational studies", Biometrics, 24, pp.295~313 (1968)
- Mantel N, "Statistical aspects of the analysis of data from retrospective studies of disease", J Natl Cancer Inst, 22, pp.719~748 (1959)
- Egger M, "Bias in meta-analysis detected by a simple, graphical test", BMJ, 315, pp.629~634 (1997)
- Zhu WL, "The study on the relationship between lipoprotein lipase gene polymorphism and hyperlipidemia in the middle-aged and aged people of Xicheng District of Beijing City", Chin J Med Genet, 19(Suppl), pp.361~362 (2002)
- Liu J, "The associations of lipoprotein lipase gene Pvu II RFLP with plasma lipids and coronary heart disease", master, pp.1999
- Zhu TB, "Relationship between lipoprotein lipase gene polymorphism and hypertriglyceridemia", Acta Univ Med Nanjing, 18, pp.297~298 (1998)
- Cui XD, "DNA polymorphism of Pvu II sites in the lipoprotein lipasegene in patients with hyper lipoidemia", Jiangxi Med J, 43, pp.16~19 (2008)
- Zhu XM, "Correlation of lipoprotein lipase gene polymorphism at Pvu II locus and plasm lipids of elderly population", Acad J Guangzhou Med Coll, 33, pp.17~20 (2005)
- Peacock RE, "Associations between lipoprotein lipase gene polymorphisms and plasma correlations of lipids, lipoproteins and lipase activities in young myocardial infarction survivors and age-matched healthy individuals from Sweden", Atherosclerosis, 97, pp.171~185 (1992)
- Hayden MR, "Gene environment interaction and plasma triglyceride levels: the crucial role of lipoprotein lipase", Clin Genet, 46, pp.15~18 (1994)
- Ukkola O, "Lipoprotein lipase polymorphisms and responses to long-term overfeeding", J Intern Med, 251, pp.429~436 (2002)
- Nicklas BJ, "Lipoprotein lipase gene variation is associated with adipose tissue lipoprotein lipase activity, and lipoprotein lipid and glucose concentrations in overweight postmenopausal women", Hum Genet, 106, pp.420~424 (2000)
- Cui LL, "Meta-analysis of LPL Pvu II polymorphism with hyperlipoidemia and coronary heart disease in the Chinese population", Yi Chuan, 32, pp.1031~1036 (2010)
- Quteineh L, "CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation", Pharmacogenomics J, 17, pp.69~75 (2017)
- Hsiao PJ, "MTTP-297H polymorphism reduced serum cholesterol but increased risk of non-alcoholic fatty liver disease-a cross-sectional study", BMC Med Genet, 16, pp.93~ (2015)